Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

Thus, the present study was aimed at investigating whether vitamin D status also determines cabergoline action on sexual function and depressive symptoms in reproductive-age women.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Potential participants were not considered for enrollment if they had prolactin-secreting macroadenomas, mixed pituitary tumors, macroprolactinemia, any other chronic diseases, psychiatric problems, premature or early menopause, developmental or acquired anomalies of the reproductive system, sexual inactivity, homosexual or bisexual orientation, undergone urogynecological operations that might have affected sexual function, were pregnant or breastfeeding, or received any treatment (with the exception of vitamin D supplements).

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Vitamin D Status Determines the Effect of Cabergoline on Sexual Function and Depressive Symptoms in Hyperprolactinemic Women

Study design awaiting verification · Nutrients · 2025

Original publication title

Vitamin D Status Determines the Effect of Cabergoline on Sexual Function and Depressive Symptoms in Hyperprolactinemic Women

Robert Krysiak; Karolina Kowalcze; Johannes Ott; Andrea Deledda; Bogusław Okopień

© 2025 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Background/Objectives: Although untreated prolactin excess is often associated with female sexual dysfunction, sexual functioning improves after chronic administration of dopamine agonists, including cabergoline. Extra-sexual benefits of cabergoline therapy were found to be less pronounced in young hyperprolactinemic women in the case of coexistent hypovitaminosis D. Thus, the present study was aimed at investigating whether vitamin D status also determines cabergoline action on sexual function and depressive symptoms in reproductive-age women. Methods: This prospective cohort study included 75 young women with prolactin excess, who, depending on vitamin D status, were assigned to one of three groups.

Females with vitamin D deficiency (group A), vitamin D-insufficient women (group B) and vitamin D-sufficient women (group C) were matched for age, body mass index, blood pressure and prolactin levels. For the following six months, they received cabergoline. Before and after cabergoline treatment, all participants completed questionnaires evaluating female sexual functioning (FSFI) and depressive symptoms (BMI-II). The remaining outcomes of interest included plasma levels of 25-hydroxyvitamin D, prolactin and sex hormones. Results: Before treatment, there were no differences between the study groups in sexual functioning and mood.

The study groups differed in post-treatment levels of 25-hydroxyvitamin D, prolactin, testosterone and estradiol. Although cabergoline reduced the total FSFI score and improved functioning in all domains of the FSFI questionnaire, this effect was strongest in group C and weakest in group A. Statistically significant changes in the BDI-II score were observed only in group C. The increase in the total FSFI score and domain scores correlated with the decrease in prolactin levels, 25-hydroxyvitamin D levels, the increase in testosterone and estradiol concentrations, and the reduction in the BDI-II score. Conclusions: Low vitamin D status attenuates the beneficial effects of cabergoline on sexual function and depressive symptoms in reproductive-age women.

An extract from the source publication. Read it in context.

At a glance

Abstract: Background/Objectives

Although untreated prolactin excess is often associated with female sexual dysfunction, sexual functioning improves after chronic administration of dopamine agonists, including cabergoline. Extra-sexual benefits of cabergoline therapy were found to be less pronounced in young hyperprolactinemic women in the case of coexistent hypovitaminosis D. Thus, the present study was aimed at investigating whether vitamin D status also determines cabergoline action on sexual function and depressive symptoms in reproductive-age women.

Source: Background/Objectives

Abstract: Results

Before treatment, there were no differences between the study groups in sexual functioning and mood. The study groups differed in post-treatment levels of 25-hydroxyvitamin D, prolactin, testosterone and estradiol. Although cabergoline reduced the total FSFI score and improved functioning in all domains of the FSFI questionnaire, this effect was strongest in group C and weakest in group A. Statistically significant changes in the BDI-II score were observed only in group C. The increase in the total FSFI score and domain scores correlated with the decrease in prolactin levels, 25-hydroxyvitamin D levels, the increase in testosterone and estradiol concentrations, and the reduction in the BDI-II score.

Source: Results

Abstract: Conclusions

Low vitamin D status attenuates the beneficial effects of cabergoline on sexual function and depressive symptoms in reproductive-age women.

Source: Conclusions:
Authors’ abstract

Background/Objectives: Although untreated prolactin excess is often associated with female sexual dysfunction, sexual functioning improves after chronic administration of dopamine agonists, including cabergoline. Extra-sexual benefits of cabergoline therapy were found to be less pronounced in young hyperprolactinemic women in the case of coexistent hypovitaminosis D. Thus, the present study was aimed at investigating whether vitamin D status also determines cabergoline action on sexual function and depressive symptoms in reproductive-age women. Methods: This prospective cohort study included 75 young women with prolactin excess, who, depending on vitamin D status, were assigned to one of three groups.

Females with vitamin D deficiency (group A), vitamin D-insufficient women (group B) and vitamin D-sufficient women (group C) were matched for age, body mass index, blood pressure and prolactin levels. For the following six months, they received cabergoline. Before and after cabergoline treatment, all participants completed questionnaires evaluating female sexual functioning (FSFI) and depressive symptoms (BMI-II). The remaining outcomes of interest included plasma levels of 25-hydroxyvitamin D, prolactin and sex hormones. Results: Before treatment, there were no differences between the study groups in sexual functioning and mood.

The study groups differed in post-treatment levels of 25-hydroxyvitamin D, prolactin, testosterone and estradiol. Although cabergoline reduced the total FSFI score and improved functioning in all domains of the FSFI questionnaire, this effect was strongest in group C and weakest in group A. Statistically significant changes in the BDI-II score were observed only in group C. The increase in the total FSFI score and domain scores correlated with the decrease in prolactin levels, 25-hydroxyvitamin D levels, the increase in testosterone and estradiol concentrations, and the reduction in the BDI-II score. Conclusions: Low vitamin D status attenuates the beneficial effects of cabergoline on sexual function and depressive symptoms in reproductive-age women.

Publication and source details

Original title: Vitamin D Status Determines the Effect of Cabergoline on Sexual Function and Depressive Symptoms in Hyperprolactinemic Women

Robert Krysiak; Karolina Kowalcze; Johannes Ott; Andrea Deledda; Bogusław Okopień

Nutrients · 2025

* Correspondence: rkrysiak@sum.edu.pl© 2025 by the authors.2025https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).Medical University of Silesia in KatowiceThe cost of publication was covered by the Medical University of Silesia in Katowice.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T01:55:14.707400+00:00

DOI: 10.3390/nu17111813 · PMC12158003